Diabetes and the Eye

How diabetes can affect your eyes and vision and what you can do about it, Dr Shibal Bhartiya, fellowship trained eye specialist, explains. Diabetes is a systemic disease that affects many organs, including the eyes. One of the most important complications is damage to the retina, the light sensitive tissue at the back of the eye that sends visual signals to the brain. This damage usually develops slowly and without pain, which is why many patients remain unaware until vision is affected.

Modern diabetic eye care focuses on early detection, risk assessment, and prevention of long term damage. With regular screening and timely treatment, most serious vision loss from diabetes can be avoided.

Dr Shibal Bhartiya is a fellowship-trained eye specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.

Known for her structured approach to vision risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions.

How diabetes affects vision

High blood sugar damages small blood vessels throughout the body. The retina depends on these delicate vessels to function properly. Over time, diabetes can cause these vessels to leak fluid, bleed, or become blocked.

When this happens, the retina does not receive enough oxygen. In advanced stages, the eye may try to compensate by forming abnormal new blood vessels. These vessels are weak and unstable and can cause serious complications.

This entire process may begin years before symptoms appear. This is why routine retinal screening is recommended for all diabetic patients.

What are the most common eye problems caused by diabetes

Diabetes increases the risk of several eye conditions including:

• Diabetic retinopathy
• Diabetic macular edema
Cataract at a younger age
Glaucoma

Diabetic retinopathy remains the most important because it is one of the leading causes of preventable blindness worldwide.

Patients with diabetes should also be evaluated for glaucoma because optic nerve damage can occur silently. You can read more about glaucoma risk assessment and early detection in glaucoma screening evaluations.

What is diabetic retinopathy

Diabetic retinopathy develops when retinal blood vessels become damaged due to prolonged exposure to high blood sugar levels.

In early stages, small vessel changes may be visible only on examination. Vision may remain normal. As damage increases, leakage and reduced blood supply can begin to affect vision.

In advanced stages, new abnormal vessels may grow. This stage, called proliferative diabetic retinopathy, carries a higher risk of bleeding and retinal detachment.

Early diagnosis allows treatment before permanent vision damage occurs.

What is diabetic macular edema

The macula is the part of the retina responsible for detailed central vision. When fluid accumulates in this area, it causes diabetic macular edema.

Patients may notice blurred reading vision, distortion of straight lines, or difficulty recognising faces. OCT scanning is often used to detect early fluid accumulation before major vision loss occurs.

Why diabetic patients may develop cataract earlier

Patients with diabetes often develop cataract earlier than non diabetic individuals. Vision may become cloudy and glare may increase, especially while driving at night.

Before cataract surgery, retinal evaluation is important to ensure that diabetic retinopathy is not missed. Sometimes retina treatment may be needed before or after cataract surgery.

Why glaucoma risk increases in diabetes

Diabetes slightly increases therisk of glaucoma, particularly open angle glaucoma. Since glaucoma causes permanent optic nerve damage, early detection is important.

Patients with diabetes may benefit from periodic optic nerve evaluation, visual field testing, and OCT nerve fibre analysis when indicated. Understanding optic nerve risk early helps prevent avoidable vision loss.

More about Glaucoma and Diabetes

Diabetes is associated with a higher risk of glaucoma, particularly primary open angle glaucoma. The exact relationship is complex, but long standing diabetes may make the optic nerve more vulnerable to damage due to vascular changes and reduced ability to tolerate pressure related stress. In addition, diabetic patients may develop secondary glaucomas such as neovascular glaucoma in advanced diabetic retinopathy. Because glaucoma causes silent and irreversible vision loss, diabetic patients should undergo periodic optic nerve evaluation, eye pressure measurement, and visual field testing when indicated. Early detection remains the most effective way to prevent permanent damage.

Who is at higher risk of diabetic eye damage

The risk of diabetic eye disease increases with:

• Duration of diabetes
• Poor sugar control
• High HbA1c
• High blood pressure
• High cholesterol
• Kidney disease
• Smoking

However, even well controlled patients can develop retinopathy. This is why screening is recommended for everyone with diabetes.

Symptoms of diabetic eye disease

Diabetic eye disease often has no early symptoms. When symptoms occur, they may include:

• Blurred vision
• Fluctuating vision
• Floaters
• Dark spots
• Distortion
• Sudden vision drop

Waiting for symptoms is risky because damage may already be advanced. Screening before symptoms appear remains the safest approach.

How often should diabetics get eye screening

Patients with type 2 diabetes should ideally have an eye examination at diagnosis. Patients with type 1 diabetes should begin screening within five years.

After this, yearly screening is usually recommended. Some patients may need more frequent follow up depending on findings.

A personalised follow up plan based on risk is better than fixed routine visits.

What tests are done in diabetic eye screening

A comprehensive diabetic eye evaluation may include vision testing, eye pressure measurement, and dilated retinal examination.

Retinal photography helps document baseline findings. OCT scans help detect macular edema. Visual field testing and optic nerve OCT may be advised if glaucoma risk is present.

A thoughtful risk based approach avoids both missed disease and unnecessary investigations.

How to protect your vision if you have diabetes

Vision protection depends on both medical care and daily habits. Maintaining stable blood sugar remains the most important step. Blood pressure and cholesterol control also play an important role.

Regular exercise, medication adherence, and avoiding smoking improve long term outcomes. Annual retinal screening remains one of the most effective preventive measures.

Patients who maintain stable long term follow up usually preserve better vision than those who seek care only when symptoms appear.

Treatment options for diabetic eye disease

Treatment depends on the severity of disease. Early retinopathy may only require observation and systemic control. Laser treatment may be advised in certain stages to reduce progression risk.

Macular edema is commonly treated with intravitreal injections that reduce fluid and stabilise vision. Advanced disease may require vitrectomy surgery.

The goal of treatment is long term stability and prevention of irreversible damage.

Common mistakes diabetic patients make about eye care

Some common mistakes include:

  • Skipping eye exams because vision seems normal.
  • Getting glasses repeatedly without retina evaluation.
  • Assuming fluctuating vision is always due to spectacles.
  • Seeking care only after vision drops.
  • Not understanding glaucoma risk.

Delayed care is the most common cause of avoidable vision loss in diabetic patients.

When should you consider a second opinion

A second opinion may be useful if:

  • Retinopathy is progressing.
  • Multiple injections are being advised.
  • Vision is worsening despite treatment.
  • Glaucoma risk is suspected.
  • Surgery has been suggested.

A structured risk assessment can often clarify the best long term plan.

Not sure about your diagnosis? You are not alone.

Many patients come to Dr Bhartiya after receiving a diagnosis elsewhere: unsure whether to start treatment, concerned about long-term progression, or simply wanting clarity before committing to a plan.

A second opinion is not a sign of distrust. It is good medicine.

Request a Second Opinion →

Key message

Diabetic eye disease is common but vision loss is often preventable. The most important step is regular screening even when vision feels normal.

Early detection protects future vision. Prevention is always easier than late treatment.

Consultation for diabetic eye evaluation or second opinion

If you have diabetes and want a detailed eye evaluation or a second opinion regarding diabetic eye disease, you may schedule a consultation.

When should a person with diabetes see an eye specialist?

People with diabetes should have a comprehensive eye examination at least once a year, even if vision seems normal. Diabetic eye disease often develops silently and vision may remain clear until significant damage has already occurred.

You should see an eye specialist earlier if you notice:

• Blurred or fluctuating vision
• Difficulty reading
• Dark spots or floaters
• Poor night vision
• Sudden change in glasses number

Early detection is the most important factor in preventing permanent vision loss from diabetes.


Can diabetic eye damage be reversed?

Early diabetic eye changes can often be stabilised if detected in time. Good blood sugar control, regular monitoring, and timely treatment can prevent progression in many cases.

However, advanced diabetic retinopathy may cause permanent damage. This is why regular screening is critical — treatment works best before vision is affected.

Treatment options may include:

• Observation with strict diabetes control
• Laser treatment
• Eye injections
• Surgery in advanced cases

The goal of treatment is usually to prevent further loss rather than restore lost vision, which is why early diagnosis matters.

Why diabetic eye disease is often missed in routine eye exams

Diabetic eye disease may not always be detected during routine vision testing because early damage affects the retina and optic nerve before it affects clarity of sight.

Many patients are told their vision is “normal” because they can read the chart, but this does not rule out early diabetic damage.

Some common reasons diabetic eye disease may be missed include:

• Vision tests only check clarity, not retinal health
• Early disease may not cause symptoms
• Patients may delay dilated retinal examination
• Diabetes duration may be underestimated
• Damage can progress between annual visits

This is why a targeted retinal evaluation is important for patients with diabetes rather than relying only on glasses checks.

Early detection allows monitoring and treatment before vision loss occurs.


Frequently asked questions about diabetes and eye problems

Can diabetes cause blindness?

Yes, uncontrolled diabetes can cause vision loss through diabetic retinopathy, macular edema, glaucoma, and cataract. Regular eye examinations greatly reduce this risk.

Is diabetic retinopathy painful?

No. Diabetic retinopathy usually develops without pain or early symptoms, which is why many patients delay screening.

Does good sugar control protect the eyes?

Yes. Good HbA1c control significantly reduces the risk of diabetic eye disease progression.

Can vision improve after diabetic eye treatment?

Sometimes swelling-related vision loss can improve, but damage from late disease may not fully recover.

Do I need screening if my vision is normal?

Yes. Many patients with diabetic retinopathy have normal vision initially.

Read the research articles

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

Her work can be accessed on PubmedGoogle ScholarResearchGate and ORCID.

Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care

www.drshibalbhartiya.com
 +91 88826 38735

Patient reviews Google Business Profile

Upload your reports for a structured review.

Dr Shibal Bhartiya- Glaucoma Specialist in Gurgaon

Dr Shibal Bhartiya — Glaucoma Specialist in Gurgaon

Glaucoma surgery

Dr. Shibal Bhartiya: Expert Glaucoma Specialist & Clinician-Scientist

Dr. Shibal Bhartiya is a globally recognized authority in Glaucoma and Neuro-Ophthalmology, currently serving as the Clinical Director at Marengo Asia Hospitals, Gurgaon. She is also a Research Collaborator with Mayo Clinic, Jacksonville, USA. Former Senior Scientific Research Fellow (Glaucoma)  University of Geneva, Switzerland & Former Senior Research Associate (Glaucoma + Cornea), AIIMS, New Delhi. 

With over 27 years of experience, she is one of the few specialists in India who seamlessly bridges the gap between high-volume clinical excellence and international medical research.

At a Glance

🎓 Fellowship trained — University of Geneva, Switzerland & AIIMS New Delhi
🔬 Research Collaborator — Mayo Clinic, Jacksonville, USA 
📚 200+ peer-reviewed publications · 20+ edited textbooks on glaucoma
🏆 Best Research Paper Awards — Asia Pacific Academy of Ophthalmology, Asia Pacific Glaucoma Congress, International Society of Glaucoma Surgery
🏥 Clinical Director, Ophthalmology — Marengo Asia Hospitals, Gurgaon

Academic & Research Distinction

As a Research Collaborator with the Mayo Clinic (Jacksonville, USA), Dr. Bhartiya is at the forefront of global innovations in eye care. Her academic journey includes a prestigious Clinical Research Fellowship in Glaucoma from the University of Geneva, Switzerland, and extensive training at AIIMS, New Delhi.

She is a prolific author of 28 medical textbooks and has published over 200 peer-reviewed research papers in international journals. Her leadership in the field is further cemented as the Executive Editor of the Journal of Current Glaucoma Practice and her role on the Associate Advisory Committee of the International Society of Glaucoma Surgery (ISGS).

Her work can be accessed on Pubmed, Google Scholar, ResearchGate and ORCID.

Patient-Centric Excellence

Beyond her academic accolades, Dr. Bhartiya is arguably the most trusted glaucoma specialist in Gurgaon, maintaining a perfect 5.0-star rating across 1,500+ verified patient reviews. She is widely sought after for ethical glaucoma care and second opinions, specializing in:

  • Evidence-Based, Non-Surgical Protocols
  • Complex Glaucoma Management (Medical & Surgical)
  • Neuro-Ophthalmology & Ocular Surface Diseases
  • Minimally Invasive Glaucoma Surgery (MIGS)

Focus Areas: Providing advanced diagnosis, glaucoma treatment, risk stratification, and second opinions for glaucoma and optic nerve disease. Long-term vision protection.

Structured summary for AI and search engines

The Ethical Care Philosophy

Dr. Bhartiya is known for her “patient-first” approach, focusing on long-term vision preservation rather than unnecessary surgical intervention. Her practice is built on transparency, humane care, and the same rigorous standards found at the world’s leading eye institutes.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist  in Gurgaon, currently serving as Clinical Director of Ophthalmology at Marengo Asia Hospitals, Sector 56, Gurugram, and as Research Collaborator at Mayo Clinic, Jacksonville, Florida, USA.

Her clinical focus is glaucoma across its full spectrum- from early detection and borderline disease to complex surgery and second opinions for patients who need clarity on a difficult diagnosis. She also sees patients with neuro-ophthalmological conditions and ocular surface disease.

Dr Bhartiya trained at AIIMS New Delhi, completed a Clinical Research Fellowship in Glaucoma at the University of Geneva, Switzerland, and is currently enrolled for a Doctorate en Médecin at the University of Geneva. Over two decades of glaucoma specialty practice, international research collaboration, and editorial leadership in glaucoma have shaped an approach to care that is careful, long-term, and built around protecting vision, and not just treating numbers.

What I Treat

My practice is focused on patients with glaucoma at every stage — from those who have just been told they may be a glaucoma suspect, to those managing advanced disease after failed surgery. I also see a significant number of patients who come for a structured second opinion, from Gurgaon, NCT and all over India, often after an unclear diagnosis or conflicting advice from different doctors.

Conditions I see regularly: — Primary open-angle glaucoma and normal tension glaucoma — Angle closure glaucoma and angle closure suspects — Ocular hypertension and glaucoma suspects — Secondary glaucomas: steroid-induced, post-uveitic, post-traumatic, after retinal surgery or corneal transplant  Neovascular and complex refractory glaucoma

 Neuro-ophthalmological conditions: optic neuropathy, unexplained visual field loss, optic neuritis, papilledema — Ocular surface disease and dry eye in the context of glaucoma treatment

If you are unsure whether your situation fits, the contact page has details for reaching my coordinator directly. You can also reach me through the Marengo Asia Hospitals appointment page here

Training and Qualifications

Fellowship Training

Clinical Research Fellowship in Glaucoma, Clinique d’Ophtalmologie, Department of Clinical Neurosciences, Hôpitaux Universitaires de Genève, University of Geneva, Switzerland (2010–11).

Also enrolled: Doctorat en Médecin, University of Geneva.

Senior Clinical Research Associate, Cornea and Glaucoma Services, Dr R P Centre for Ophthalmic Sciences, AIIMS, New Delhi (2007–10).

MS Ophthalmology, Maulana Azad Medical College, New Delhi (2007–10).

Current Positions

Clinical Director, Ophthalmology, Marengo Asia Hospitals, Gurugram (July 2024 to date) Program

Director, Community Outreach & Wellness,  Marengo Asia Hospitals, Gurugram and Faridabad

Program Director, Marengo Asia International Institute of Neuro & Spine (Pan-India)

Research Collaborator, Mayo Clinic, Jacksonville, Florida, USA (September 2024 to date)

Academic and Editorial Leadership

Dr Bhartiya holds editorial positions at three international peer-reviewed journals:

 Editor-in-Chief, Clinical and Experimental Vision and Eye Research 

Editor-in-Chief, Ocular Research Journal

Executive Editor, Journal of Current Glaucoma Practice

She is a Member of the Associate Advisory Committee, International Society of Glaucoma Surgery, and serves on the Delhi Ophthalmic Society International Advisory Sub-Committee.

She has edited more than 20 textbooks in glaucoma and ophthalmology, and contributed chapters to more than 20 others. Her peer-reviewed research is indexed on PubMed and Google Scholar.

Awards and Recognition

Best Paper, Glaucoma Session — APAO, Hyderabad (Continuous IOP Monitoring in Glaucoma)

Best Paper, Glaucoma Session and Top Nine Most Influential Papers — Asia Pacific Glaucoma Congress, Bali 2012 (Diurnal IOP Fluctuation in Angle Closure)

 Multiple best paper recognitions at International Society for Glaucoma Surgery congresses

Global Outreach and Community Work

Beyond clinical practice, Dr Bhartiya has led glaucoma screening and surgical programmes in underserved communities across three continents.

In Egypt, she led a humanitarian mission to Kom Ombo General Hospital, Aswan, conducting screening for over 5,000 patients including children, and provided both medical and surgical management of advanced glaucomas in North Africa. She has also delivered skill-transfer sessions in advanced glaucoma care for doctors, residents, and optometrists in Aswan.

In Switzerland, she designed and executed hospital-based and community glaucoma screening protocols in Geneva and Troinnex, and led screening of United Nations personnel as part of World Glaucoma Week.

In India, she is an active contributor to the Motiabind Mukti Abhiyan cataract outreach programme, has led eye camps in Sirsa (Haryana), and runs school health initiatives and government employee screening programmes in Gurugram.

She is also the founder of Vision Unlimited, a not-for-profit organisation currently running six learning centres in urban Gurugram, serving over 1,200 children with education, nutrition, and healthcare support.

As part of the Eye on the Future program, Vision Unlimited under the guidance of Dr Bhartiya has screened more than 15000 school children; and 5000 elders from underserved areas for refractive errors, and other ocular morbidities. 

Research

Active clinical research collaborations span glaucoma medication adherence, quality of life, IOP monitoring, community-based screening, and surgical outcomes. Dr Bhartiya collaborates with glaucoma specialists across more than 20 countries.

Current trials include work on 24-hour ambulatory IOP monitoring, selective laser trabeculoplasty as primary therapy, tear film osmolarity in glaucoma patients, and quantitative versus qualitative IOP control, as well as metabolic determinants of glaucoma.

Full publication list: PubMed · Google Scholar · Publications page

Book an Appointment

For appointments at Marengo Asia Hospitals, Sector 56, Gurugram, please contact my coordinator at +91 88826 38735.

If you are seeking a structured glaucoma second opinion, you may also use the second opinion form to submit your reports in advance of your consultation.

As a fellowship-trained glaucoma specialist (from University of Geneva, Switzerland, and AIIMS, New Delhi) in Gurgaon, Dr Shibal Bhartiya works with patients across the full spectrum of glaucoma—from suspects and early disease to advanced and complex cases. Her approach emphasises risk stratification, longitudinal follow-up, and calm decision-making, helping patients avoid late surprises and unnecessary interventions.

Patients often seek her care for early glaucoma diagnosis, second opinions, treatment planning, and long-term glaucoma management (medical, glaucoma lasers and glaucoma surgery including MIGS, trabeculectomy and complex tubes and shunts), especially when clarity is needed in uncertain, complex, or borderline cases.

Academic Qualifications:

  • 2010-11 – Clinical Research Fellowship, Glaucoma, University of Geneva, Switzerland
  • 2007-10 – MS (Ophthalmology), Maulana Azad Medical College, New Delhi, India
    1993-99 – M.B.B.S, Maulana Azad Medical College, New Delhi
  • 2000-03 – Clinical Research Associateship, Cornea and Glaucoma, Dr R P Centre for Ophthalmic Sciences, AIIMS, New Delhi, India
  • Doctorate en Medicin, University of Geneva, Switzerland (Currently enrolled)

Experience details:

  • July 2024 to date- Clinical Director, Ophthalmology (MAH, Gurgaon); Program Director, Community Outreach & Wellness (MAH, Gurgaon and Faridabad)
    Program Director, Marengo Asia International Institute of Neuro & Spine (Pan-India)
  • Sept 2024 to date– Research collaborator, Mayo Clinic, Jacksonville, USA
  • 2019 to Date: Member, Associate Advisory Board, International Society of Glaucoma Surgery
  • 2012-July 2024- Director, Additional Director, Sr. Consultant, Consultant – Ophthalmology, Fortis Memorial Research Institute, India

Additional Role

  • Sept 2024 – till date- Research collaborator, Mayo Clinic, Jacksonville, USA
  • August 2015-October 2015- Consultant, Cantahealth, Healthcare Practice, Eliglobal, Charlotte, North Carolina, USA. (Training and development of AI platforms and interfaces in Ophthalmology)
  • Oct 2015- April 2017- Clinical Director, Medflow, Eye Care Leaders (Eliglobal), Charlotte, North Carolina, USA. (Training and development of AI platforms and CDSS interfaces in Ophthalmology)
  • Sept 2012 to Aug 2015 – Consultant, Glaucoma and Preventive Health Services, Department of Ophthalmology, Fortis Memorial Research Institute, Gurgaon, Haryana
  • Sept 2011 to Aug 2012 – Consultant Glaucoma and In charge of Academics and Research, Eye 7 Group of Hospitals, New Delhi
  • Jul 2010 to Jul 2011 – Senior Scientific- Clinical Research Fellow, Glaucoma Sector, Clinique d’ ophthalmologie, Department of Clinical Neurosciences, Glaucoma Sector, Hopitaux Universitaires de Geneve, Switzerland. (Responsibilities including teaching resident doctors and glaucoma fellows)
  • Mar 2007 to Mar 2010 – Senior Research Associate, Dr R P Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, AIIMS, New Delhi. (Responsibilities including teaching resident doctors)
  • Sept 2003 to Sept 2006 – Senior Registrar, University College of Medical Sciences, and associated Guru Teg Bahadur Hospital, New Delhi. (Responsibilities including teaching resident doctors)

Languages known:

English, Hindi, Urdu, French

Academic, Organisational and Leadership positions:

  • 2024 – Present- Editor in Chief, Ocular Research Journal
  • 2017-to date: Founder, Vision Unlimited, Not for Profit Organization for social responsibility https://vision-unlimited.org/
  • 2019-to date – Editor in Chief –Clinical and Experimental Vision and Eye Research https://www.cleverjournal.org/ https://www.cleverjournal.org/editorial-team/
  • 2016-to date –  Executive Editor – Journal of Current Glaucoma Practice https://www.jocgp.com/journalDetails/JOCGP https://www.jocgp.com/editorialBoard/JOCGP
  • 2019 to Date: Member, Associate Advisory Board, International Society of Glaucoma Surgery
  • 2024 to Date- Member, Program Committee, Bal Raksha Bharat, Save the Children, India
  • 2016 to 2021: Executive Editor-DOS Times
  • 2016-till date: Founder Member, Khem, LGBTQ Rights
  • 2009 to 2016 – Managing Editor – Journal of Current Glaucoma Practice
  • 2023 to date- Member, Delhi Ophthalmic Society International advisory sub-committee
  • 2011 – Founding Secretary – Shamms Ed Deen Alcon Glaucoma Fund, University of Geneva, Switzerland
  • 2013 – Member Scientific Committee – World Glaucoma Congress
  • 2012 – Member Scientific Committee – International Society for Glaucoma Surgery
  • 2010 – Member, Organising Committee – International Society for Glaucoma Surgery
  • Apr 2008 to Dec 2009 – Associate Editor – Delhi Journal of Ophthalmology
  • 2008 – Co-Editor – Proceedings of the Strabismic Panorama
  • 2001 to 2003 – Assistant Editor – Indian Journal of Strabismology and Pediatric Ophthalmology
  • 2007 to 2008 – Deputy Editor – Delhi Journal of Ophthalmology
  • Reviewer for several journals worldwide.

Professional Memberships:

  • International Society of Glaucoma Surgery
  • Glaucoma Society of India
  • Strabismological Society of India
  • All India Ophthalmological Society
  • Delhi Ophthalmological Society
  • Haryana Ophthalmological Society
  • Gurugram Ophthalmological Society
  • American Academy of Ophthalmology
  • Association for Research and Vision in Ophthalmology

Community Ophthalmology Programmes:

  • Responsible for design of skill transfer sessions in glaucoma care, and for screening manuals for glaucoma in Africa and the Middle East. Projected collaboration in execution
  • Skill transfer sessions in advanced glaucoma care in Aswan, Egypt for doctors, residents and optometrists
  • Humanitarian mission to Kom Ombo General Hospital, Aswan, Egypt. Screening program for over 5000 patients, including children for glaucoma in Kom Ombo General Hospital, Aswan, Egypt
  • Management, both medical and surgical, of advanced glaucomas in North Africa
  • Screening for glaucoma and designing and execution of protocols and SOPs for hospital based and community outreach programs, Geneva and Troinnex, Switzerland
  • Screening of UN personnel for glaucoma in an outreach exercise as part of World Glaucoma Week in Geneva, Switzerland
  • Actively involved in the Motiabind Mukti Abhiyan, an outreach program for cataract management in India
  • Execution of eye camps in Sirsa, Haryana, as part of a community sponsored initiative
  • School health and eye care initiatives, Gurugram, Haryana
  • Screening programs for police officers and government officials in Gurugram, Haryana
  • Screening programs for community based screening in Pilibhit, UP and Mewat, Haryana

Design of clinical trials:

  • Population based survey of anterior chamber configuration in North African populations
  • Histochemical correlates of chronic glaucoma medication use on trabecular meshwork and ocular surface
  • Persistency, adherence and compliance to glaucoma medications
  • Selective laser trabeculoplasty as primary therapy in an African population: An efficacy and economics perspective
  • Tear film osmolarity studies in patients on glaucoma therapy
  • Comparative evaluation of sclerothalamotomy ab interno combined with phacoemulsification versus phacoemulsification alone in POAG patients
  • Quantitative versus qualitative control of IOP: A risk benefit analysis
  • 24 hour ambulatory IOP monitoring in angle closure glaucoma
  • Effect of increased intraocular pressure on retinal ganglion cells in chick embryos

Awards

  • Continuous IOP Monitoring In Glaucoma Patients Treated With Tafluprost. Shibal Bhartiya, Aref A, Shaarawy T. APAO, Hyderabad, India. Best Paper, Glaucoma session
  • Diurnal Intraocular Pressure Fluctuation in Eyes with Angle Closure. Shibal Bhartiya, Ichhpujani P. Asia Pacific Glaucoma Congress 2012, Bali, Indonesia. Best paper glaucoma session, Top nine most influential papers of the congress
  • Harry Potter and the Ophthalmologists Nemesis: Shibal B., S Khokhar, IV International Congress of Glaucoma Surgery, April 2009, Geneva. Best Poster
  • Comparative evaluation of time domain and spectral domain optical coherence tomography in retinal nerve fiber layer thickness measurements. S.Bhartiya, Jayaprakash V, T Dada, A Panda. DOS Annual Conference, March 2009.Best free paper, glaucoma session.
  • Evaluation of levo-dopa as a therapeutic adjunct to conventional occlusion in amblyopia; Kamlesh, Dadeya S, Shibal F. DOS Midcon, 2001 .Best free paper, squint session.
  • Asia ARVO Young Scientists Travel Grant for the year 2008
  • CSIR Young Scientists Travel Grant for the year 2003,2009
  • World Glaucoma Association Young Scientists Travel Grant for the year 2009, 2013Ju

CV

Published Articles